Supernus Pharmaceuticals (NASDAQ:SUPN) Director Sells $271,725.09 in Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Frederick Hudson sold 5,369 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $50.61, for a total value of $271,725.09. Following the transaction, the director directly owned 60,413 shares of the company’s stock, valued at approximately $3,057,501.93. The trade was a 8.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN opened at $49.29 on Thursday. The company’s fifty day moving average is $51.22 and its 200-day moving average is $49.17. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $59.68. The company has a market capitalization of $2.84 billion, a PE ratio of -72.48, a P/E/G ratio of 1.58 and a beta of 0.70.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rubric Capital Management LP bought a new position in shares of Supernus Pharmaceuticals in the second quarter worth about $21,908,000. Woodline Partners LP grew its stake in shares of Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after purchasing an additional 490,835 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Supernus Pharmaceuticals by 67.1% in the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after purchasing an additional 338,584 shares in the last quarter. Morgan Stanley increased its holdings in shares of Supernus Pharmaceuticals by 42.9% in the fourth quarter. Morgan Stanley now owns 1,079,471 shares of the specialty pharmaceutical company’s stock valued at $53,650,000 after purchasing an additional 324,154 shares in the last quarter. Finally, UBS Group AG raised its position in Supernus Pharmaceuticals by 137.6% in the 3rd quarter. UBS Group AG now owns 540,123 shares of the specialty pharmaceutical company’s stock worth $25,812,000 after purchasing an additional 312,775 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday, March 8th. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Finally, Stifel Nicolaus raised their price target on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday, December 19th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $62.17.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.